A new analysis of a large data set compiled by Kaiser Permanente suggests that combining PSA data with genetic risk data may offer a much more effective way to assess risk for clinically significant prostate cancer. Now it is probably fair to say that many American consumers would have been dubious about the chances that […]![]()
